Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839425 | 0.91 | CHEK2 (0.35) | CHEK2HDAC6 | |
| SCHEMBL4842378 | 0.84 | CHEK2 (0.38) | CHEK2 | |
| SCHEMBL4841843 | 0.84 | CHEK2 (0.32) | CHEK2HDAC6 | |
| SCHEMBL4844169 | 0.83 | CHEK2 (0.37) | CHEK2 | |
| SCHEMBL4844120 | 0.82 | CHEK2 (0.36) | CHEK2 | |
| SCHEMBL5257250 | 0.82 | MEN1 (0.42) | CHEK2 | |
| SCHEMBL4834997 | 0.80 | HDAC6 (0.36) | CHEK2HDAC6 | |
| SCHEMBL4845506 | 0.79 | KCNH2 (0.32) | CHEK2HDAC6 | |
| Trifluoroacetic Acid SCHEMBL4841798 | 0.79 | MEN1 (0.53) | CHEK2 | |
| Trifluoroacetic Acid SCHEMBL4843666 | 0.78 | KMT2A (0.41) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | CHEK2 309/4885HDAC6 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.